Stock Price Prediction

ALDX stock is currently trading at $5.25, reflecting a slight post-market recovery (+0.10%) after a regular session drop of -2.96%. Bulls are optimistic due to the FDA's acceptance of Aldeyra's resubmitted NDA for reproxalap, with a PDUFA date set for April 2, 2025, which could significantly boost the stock if approved. Additionally, the expanded partnership with AbbVie, including potential milestone payments of up to $300 million, strengthens its long-term growth prospects.

ALDX stock currently faces bearish sentiment due to uncertainty surrounding the FDA's decision on reproxalap, with the PDUFA date set for April 2, 2025. The stock may see downward pressure in the short term, as speculative investors could exit before the decision, especially given the lack of immediate catalysts. A potential support level could be around $5.50, reflecting cautious sentiment until regulatory clarity emerges.

The market consensus for ALDX's eps in the upcoming quarter is projected to be approximately $0.22 USD.